Merck Flexeril 5 Mg Efficacy For Back, Neck Pain Shown In Two Trials
This article was originally published in The Tan Sheet
Executive Summary
The efficacy of Merck's muscle relaxant Flexeril 5 mg (cyclobenzaprine) in the treatment of back and neck pain is shown in two studies conducted by the company in support of the Rx-to-OTC switch candidate. The results of the studies were presented at a meeting of FDA's Nonprescription Drugs and Arthritis Advisory Committees in Gaithersburg, Md. July 20. Merck filed the NDA for Flexeril 5 mg (21-070) last Dec. 19.